Indeed, treatment with monoclonal antibodies against IL-17A or IL-17A receptors was shown to reduce the occurrence of DUs and ameliorate skin fibrosis, while selective IL-23 inhibition with guselkumab resulted in a significant improvement in SSc NVC patterns [107,108,109]. The gene discussed is IL17A; the disease is systemic sclerosis.